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Background: The purpose of this study was to describe anterior segment changes in a 
prospective, interventional, noncomparative case series of patients with neovascular glaucoma 
secondary to proliferative diabetic retinopathy treated with intravitreal bevacizumab.
Methods: Five consecutive patients with neovascular glaucoma and a refractory,   symptomatic 
elevation of intraocular pressure and pronounced anterior segment congestion received 
  intravitreal bevacizumab 1.25 mg/0.05 mL. Follow-up examinations were performed at 4–16 
weeks by the same specialists, with testing performed at hour 48, week 1, and months 1, 3, and 
6 after intravitreal bevacizumab.
Results: We observed a significant difference (P = 0.021) between initial and mean 
neovascularization at three months in all the quadrants. At three months, median intraocular 
pressure was 19 ± 5.38 (range 12–26) mmHg. In three of the five cases, diode laser cyclophoto-
coagulation was required, and in one case a trabeculectomy was performed. One patient showed 
complete synechial angle closure 48 hours after treatment which required cyclodestructive 
procedures to normalize intraocular pressure.
Conclusion: Intravitreal bevacizumab achieves complete regression of neovascularization 
in neovascular glaucoma secondary to proliferative diabetic retinopathy, and this regression 
is stable when associated with treatment of the underlying disease and should be investigated 
more thoroughly as an adjunct in the management of neovascular glaucoma.
Keywords: rubeosis, neovascular, glaucoma, bevacizumab, Avastin®, intravitreal, angle   closure, 
complications
Introduction
Neovascular glaucoma is a secondary form of glaucoma, and in 97% of cases is due to 
retinal ischemia secondary to diabetic retinopathy or to central retinal vein occlusion.1,2 
This clinical entity has a poor prognosis and is difficult to treat either medically or 
surgically, despite numerous efforts in this field.
We are seeing a growing number of case series reporting use of bevacizumab in the 
treatment of neovascular glaucoma secondary to proliferative diabetic retinopathy or 
central retinal vein occlusion, where the authors concur that there is a rapid regression 
of iris neovessels and iridocorneal angle neovascularization after administration of 
intraocular antiangiogenic agents.3–12 Some studies show a reduction of intraocular 
pressure, resolution of vitreous hemorrhage, and absence of neovascular leakage 
by iris fluorescein angiography at the end of follow-up.13–16 However, there is little 
information about the possible complications of this form of treatment for neovascular 
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We conducted a prospective study of patients diagnosed 
with neovascular glaucoma secondary to proliferative 
diabetic retinopathy in order to describe anterior segment 
changes after intravitreal bevacizumab administration.
Materials and methods
We performed a prospective, interventional, noncomparative 
study of five consecutive patients diagnosed with neovascular 
glaucoma secondary to proliferative diabetic retinopathy 
who were treated between March and September 2007. 
Approval was obtained prior to initiation of this study by the 
institutional review board of the Barraquer Ophthalmology 
Centre. Informed consent was signed by all the patients for 
treatment with intravitreal bevacizumab and inclusion in the 
study. Bevacizumab was administered in the operating room 
under topical anesthetic by intravitreal injection of 0.05 mL 
(1.25 mg) of a commercial preparation (Avastin®, Genetech 
Inc, San Francisco, CA).
The primary objective was to evaluate regression of the 
iris and iridocorneal angle neovessels and angular structural 
changes, as well as variations in intraocular pressure and 
visual acuity after one intravitreal dose of bevacizumab 
1.25 mg in patients diagnosed with neovascular glaucoma 
secondary to proliferative diabetic retinopathy. Initially, all 
patients underwent complete ophthalmologic examination 
by glaucoma and vitreous-retina specialists, and were 
then referred to an internist for systemic evaluation 
and treatment. All patients were followed by the same 
specialists, with testing performed at hour 48, week 1, and 
months 1, 3, and 6 after intravitreal bevacizumab. Panretinal 
photocoagulation or peripheral retinal cryocoagulation was 
performed beginining one week after intravitreal beva-
cizumab in order not to mask the initial acute effects of 
intravitreal bevacizumab.
Evolution of neovascularization was monitored by serial 
iris photography and gonioscopy. Anatomical structures 
of the iris (margin, stroma, periphery) and the angle were 
divided into four quadrants; the presence of neovascular-
ization was scored on a scale of 0 to 4 points, according to 
the number of quadrants affected (1 point = one quadrant). 
The degree of angular amplitude variation was measured by 
anterior segment optical coherence tomography (Visante®, 
Zeiss Optical Systems) at 0°, 90°, 180°, and 270° before and 
after treatment.
Statistical analysis was performed using the t-test 
and Mann–Whitney U test for continuous variables, and 
the Chi-square test was used for discrete variables. Only 
P values , 0.05 were considered statistically significant.
Results
Five eyes from five patients (four women and one man) aged 
62.5 ± 6.26 (53–69) years were treated. Mean follow-up 
was 20.4 (range 1–32) weeks. At the end of follow-up, four 
cases showed complete remission of rubeosis and angular 
neovascularization, with a mean intraocular pressure of 
17.8 ± 5.38 mmHg. We did not observe any secondary 
systemic effects.
Initial visual acuity varied from light perception to 
20/50; two eyes remained stable, two deteriorated, and one 
case showed improved visual acuity after treatment. In all 
cases, retinal photocoagulation was completed within the 
first month after intravitreal bevacizumab. In one case, pars 
plana vitrectomy was performed due to massive vitreous 
hemorrhage.
Initial median intraocular pressure was 23 ± 11.32 
(range 17–45) mmHg under maximum topical and sys-
temic medication, increasing to 50 mmHg at 48 hours. 
At three months, median intraocular pressure was 19 ± 5.38 
(12–26) mmHg. In three of the five cases, diode laser 
cyclophotocoagulation was required, and in one case a 
trabeculectomy was performed. Only one case remained 
normotensive with no more than topical treatment.
We observed a significant (P = 0.021) difference between 
initial and mean neovascularization at three months in all 
the quadrants. In three cases, remission was complete at 
48 hours; in four eyes, this was complete and stable until the 
third month, and one eye showed neovascular relapse in one 
of the quadrants. In all cases, the most affected anatomical 
structure was the iris margin. Intraocular pressure and 
neovascularization evolution are shown in Tables 1 and 2. 
The degree of angular goniosynechia at baseline was 360° in 
two of patients, none in two patients, and 180° in one patient. 
No patient showed any increase in angular goniosynechia 
after treatment.
In two cases, we detected a slight decrease in anterior 
chamber amplitude and a global reduction of the iridocorneal 
angle with incomplete angle closure. One patient (case 5) 
showed complete synechial angle closure 48 hours after 
treatment which required cyclodestructive procedures to 
normalize intraocular pressure, and is described here.
Case report
Patient 5 was a 61-year-old man with a 20-year history of 
poorly controlled diabetes mellitus presented with proliferative 
diabetic retinopathy previously treated with partial peripheral 
panretinal photocoagulation and cryocoagulation. He had 
neovascular glaucoma with rubeosis in the entire iris and Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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angle, with an intraocular pressure of 23 mmHg on maximum 
topical and systemic therapy. At 48 hours after intravitreal 
bevacizumab, we observed a decrease in anterior chamber 
amplitude as well as complete synechial angle closure (see 
Figures 1 and 2), and his intraocular pressure had increased 
to 50 mmHg. Diode laser cycloablation of the ciliary body 
was performed.
Discussion
Intravitreal bevacizumab is now a frequently used drug 
for the combined treatment of neovascular glaucoma.6–11,18 
In our study, three of five cases required diode laser cyclo-
photocoagulation in the first three to five days following 
intravitreal bevacizumab to control intraocular pressure 
elevations which were refractory to any medical treatment. 
Rubeosis diminished in the first 48 hours after intravitreal 
bevacizumab, possibly due to nonperfusion of the neovessels 
rather than complete disappearance, because some of the 
serial photographs clearly showed the re-emergence of the 
neovessels. The angle was the anatomical structure most 
severely affected, but also showed the most rapid regression. 
Complete resolution of rubeosis occurred in four cases, which 
supports the idea that bevacizumab could be used to decrease 
the vascular endothelial growth factor concentration and to 
induce regression of rubeosis and neovascularization of the 
iridocorneal angle.
Overall, the results are similar to those of other   published 
series regarding immediate neovascular regression after 
intravitreal bevacizumab, with an initial increase and sub-
sequent short-term reduction of intraocular pressure.3–8,10–14,16 
However, only one paper reports acute angle closure glaucoma 
as a complication of intravitreal injection of bevacizumab.17 
We consider this point especially interesting, because this 
was observed in three of five cases in our series. We suggest 
that bevacizumab-induced neovascular collapse induces 
fibrovascular contraction and anterior displacement of the 
iris-body ciliary-zonular complex. This structural alteration 
reduces anterior chamber and iridocorneal amplitude, with 
a possible decompensation of intraocular pressure due to 
loss of the angular structures. In our experience, anterior 
segment optical coherence tomography is a valuable tool for 
monitoring the angle status.
Although intraocular pressure after intravitreal beva-
cizumab remained unchanged in two cases, the other 
three showed marked increases at the first follow-up visit 
at 48 hours. This decompensation could be related to a 
decrease in angular amplitude, observed by anterior   segment 
optical coherence tomography, although prospective 
randomized studies with larger sample sizes would be 
necessary to confirm a possible relationship between 
regressed neovascularization and angle contraction due to 
the treatment.
Table 1 intravitreal bevacizumab in the treatment of neovascular glaucoma due to proliferative diabetic retinopathy: review of a series 
of five cases
Case Age  
(years)
Gender IOP Glaucoma  
Procedure
BCVA DRP  
treatment
Follow-up 
(weeks) Pre IVB 48 hours End Pre IVB End
1 64 F 19 20 16 Trabeculectomy 0.45 0.2 PPV + PCG 20
2 69 F 45 56 26 Cyclophotocoagulation HM HM None 15
3 67 F 17 16 17 None 0.3 0.4 PCG + CCG 20
4 53 F 30 60 12 Cyclophotocoagulation HM HM PCG 15
5 61 M 23 50 14 Cyclophotocoagulation 0.3 0.25 PCG 32
Abbreviations: iOP, intraocular pressure; iVB, intravitreal bevacizumab; BCVA, best corrected visual acuity; DrP, diabetic retinopathy; F, female; M, male; HM, hand 
motion; PPV, pars plana vitrectomy; PCG, photocoagulation; CCG, cryocoagulation.
Table 2 intravitreal bevacizumab in the treatment of neovascular glaucoma due to proliferative diabetic retinopathy: Variations in 
neovascularization according to angle and anterior chamber
Case Neovascularization by quadrants Variation after IVB
Pre IVB 48 hours post IVB End follow-up Angle Anterior chamber
M S P A M S P A M S P A
1 4/4 – – – – – – – – – – – Decreased stable
2 2/4
2/4 – 2/4 – – – – – – – – Decreased Decreased
3 4/4 – – 2/4 – – – – – – – – stable stable
4 4/4 – – – – – – – – – – – stable stable
5 4/4
2/4
2/4
2/4 – – 1/4
1/4
1/4 – – – Decreased Decreased
Abbreviations: iVB, intravitreal bevacizumab; M, iris margin; s, iris stroma; P, iris periphery; A, angle.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Figure 1 Case 5. Anterior chamber image obtained by anterior segment optical coherence tomography prior to treatment. Notice the narrow but open angle.
Figure 2 Case 5. Anterior segment optical coherence tomography obtained 48 hours following treatment showing complete angular closure.Clinical Ophthalmology
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Intraocular pressure values at the end of follow-up were 
clearly modified by surgical procedures aimed at maintaining 
these values within normal limits. The reduction observed 
at the end of follow-up can not only be related to treatment 
with intravitreal bevacizumab, but also to a combination 
of this treatment and the surgical procedures used.8,19–21 
  Intravitreal bevacizumab could improve visual outcomes 
and decrease the need for glaucoma surgery.22 Regression of 
neovascularization in four of our cases was noted throughout 
the three months of follow-up, probably due to treatment for 
diabetic retinopathy being performed in the first month after 
intravitreal bevacizumab.
It may be concluded that intravitreal bevacizumab 
achieves a significant regression of neovascularization in 
neovascular glaucoma secondary to proliferative diabetic 
retinopathy, and this regression is stable when associated 
with treatment of the underlying disease. In some cases, we 
observed increased intraocular pressure with a poor response 
to topical and/or systemic treatment, associated with reduction 
of the anterior chamber and the iridocorneal angle. Therefore, 
we recommend performing a complete evaluation of the extent 
of neovascularization and degree of angular goniosynechia in 
order to reduce the possibility of inducing complete angular 
closure prior to bevacizumab administration, and careful 
monitoring of the intraocular   pressure in the first 48 hours 
  following treatment is needed. We also believe that the 
maximum degree of neovascularization allowing the com-
pletely safe use of bevacizumab remains to be determined.
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